Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
Clinical trial NCT04894825 · UNKNOWN
Trial details
- NCT number
- NCT04894825
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-11
- Primary completion
- 2024-07-30
- Enrollment
- 152
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.